Replies to post #339 on Equity Field Notes from temporal sources

[DanWebzster]

AFMD signed a POTENTIALLY lucrative deal with RHHBY and spiked 220%

The deal is for development using the company's ROCK platform and does not include any of AFMDs lead programs. $96mn is front loaded into the $5B potential payout.

The lead programs hold significant value in their own rights and this deal lends substance to their prospects.

AFM13 has had promising efficacy in 2 early stage trials both as a monotherapy and a combo therapy.

Both of AFMD lead programs will have data before EOY/18. Part of this spike is based on the hope that one of these prrograms will garner an expedited path to FDA approval.

As for the RHHBY deal, it only extends the operational runway thru 2019. I think any further good news in 2018 is mostly built in.